Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

NativeMed vs Zealthy

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.1

NativeMed

Best for buyers comfortable with sub-$200 promotional compounded GLP-1 pricing who can verify pharmacy partner identity directly with NativeMed support before subscribing
★★★3.6

Starting at $149/mo

Compounded SemaglutideCompounded TirzepatideLegitScript CertifiedCash Pay
Visit NativeMed
4.8

Zealthy

Best for not currently recommended — listed for transparency and reader awareness only
★★☆☆☆2.4

Starting at $286/mo

CompoundedSemaglutideTirzepatide
Visit Zealthy

Side-by-Side Comparison

FeatureNativeMedZealthy
Overall Score7.1/104.8/10
Starting Price$149/mo$286/mo
Editorial Rating3.6 ★ /52.4 ★ /5
Features4 features3 features
States Available034
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNone2 warnings

Pros & Cons

NativeMed

Pros

  • LegitScript certified per the homepage footer (independently verifiable)
  • Promotional pricing publicly displayed: $149/mo semaglutide, $183/mo tirzepatide (sale from $299/$399 regular)
  • Async questionnaire workflow with synchronous visit triggered when state law requires it

Cons

  • Pharmacy partners are NOT publicly named — material gap for YMYL disclosure (described only as 'USA-based pharmacies' / 'accredited pharmacies')
  • States served list is not publicly enumerated
  • Pricing displayed as promotional sale price — readers should confirm whether the $149/$183 holds beyond the first month or escalates to the $299/$399 'regular' price
  • Trustpilot reviews displayed on homepage — we do NOT cite Trustpilot as a primary source per editorial policy

Zealthy

Pros

  • 34 states served — meaningful nationwide footprint
  • Asynchronous model removes friction for patients comfortable without a synchronous video visit
  • Independent licensed prescribers retain full clinical authority

Cons

  • TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
  • Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
  • Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
  • Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
  • Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
  • Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
  • Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option

Our Verdict

Winner: NativeMedScore: 7.1/10

NativeMed edges out Zealthy with a higher overall score of 7.1/10 and is particularly strong for buyers comfortable with sub-$200 promotional compounded GLP-1 pricing who can verify pharmacy partner identity directly with NativeMed support before subscribing. Zealthy remains a solid alternative, especially if you're looking for not currently recommended — listed for transparency and reader awareness only.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.